candesartan has been researched along with Acute Ischemic Stroke in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y | 1 |
| Lang, Y | 1 |
| Zhang, H | 1 |
| Li, Y | 1 |
| Liu, X | 1 |
| Li, M | 1 |
1 other study available for candesartan and Acute Ischemic Stroke
| Article | Year |
|---|---|
Candesartan Reduces Neuronal Apoptosis Caused by Ischemic Stroke via Regulating the FFAR1/ITGA4 Pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Biphenyl Compounds; Caspase 3; Gluco | 2022 |